You are here

  • Home
  • Archive
  • Volume 11, Issue 2
  • SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer

 

Online download statistics by month:

Online download statistics by month: February 2023 to July 2025

AbstractFullPdf
Feb 202334434845
Mar 2023373377105
Apr 202317217251
May 202316816976
Jun 202315115248
Jul 202315115357
Aug 202321021058
Sep 202315215328
Oct 202311111166
Nov 202316717149
Dec 202313715349
Jan 2024989869
Feb 2024757643
Mar 202411211299
Apr 20249910042
May 202410310355
Jun 202410710849
Jul 202413914051
Aug 2024949329
Sep 202411511824
Oct 202415815955
Nov 202420120454
Dec 202421922049
Jan 202517917970
Feb 202528528663
Mar 202511711745
Apr 202514014045
May 2025717637
Jun 2025737323
Jul 2025220
Total452345731534